Shay Shemesh
Founder chez NUVECTIS PHARMA, INC.
Fortune : 12 M $ au 31/03/2024
Profil
Shay Shemesh has founded Nuvectis Pharma, Inc. in 2020, where he currently holds the titles of Chief Development, Operations Officer & EVP.
He previously worked as Head-Clinical Operations at Keryx Biopharmaceuticals, Inc. and as Senior VP-Clinical & Regulatory Affairs at Stemline Therapeutics, Inc. from 2015 to 2020.
Mr. Shemesh has an undergraduate and graduate degree from Bar-Ilan University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NUVECTIS PHARMA, INC.
8,40% | 03/01/2024 | 1 491 955 ( 8,40% ) | 12 M $ | 31/03/2024 |
Postes actifs de Shay Shemesh
| Sociétés | Poste | Début |
|---|---|---|
| NUVECTIS PHARMA, INC. | Founder | 27/07/2020 |
Anciens postes connus de Shay Shemesh
| Sociétés | Poste | Fin |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2020 |
| KERYX BIOPHARMACEUTICALS | Chief Tech/Sci/R&D Officer | - |
Formation de Shay Shemesh
| Bar-Ilan University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
| Nuvectis Pharma, Inc. |
